Case Challenges in Rheumatoid Arthritis: Managing Failure of Methotrexate and TNF Inhibitor Therapy
RheumatologyThe Rheumatoid Arthritis Vital Education Initiative: New Horizons in Therapeutic Options (RAVE New Horizons)
1.0 AMA PRA Category 1 Credit(s) ™
February 07, 2019
The accreditation for this activity has expired.
Primary Audience:
This activity is for rheumatologists; PAs; NPs and nurses in rheumatology practices and some internal medicine clinicians
Relevant Terms:
rheumatology; rheumatoid arthritis
Jonathan Samuels, MD
Jonathan Samuels, MD
Associate Professor of Medicine
Division of Rheumatology
NYU Langone Health
New York, NY
Dr. Samuels is a Associate Professor in the Department of Medicine (Rheumatology), working with rheumatoid arthritis (RA) patients in many capacities over the last 8 years. He spent a few years, during a fellowship at Cornell, focusing on a translational research study about B cell tolerance in RA, and enrolling clinic patients. The last 4 years Dr. Samuels has treated a large number of RA patients at NYU Langone Health, and participated in a number of clinical trials involving RA patients. Dr. Samuels also teaches medical students, residents and fellows throughout the year, and have given lectures on extra-articular manifestations and comorbidities of RA. He uses musculoskeletal ultrasound in his practice for diagnostic help and procedure (joint injection/aspiration) guidance, and teaches this technique to rheumatologists at conferences throughout the country.
He has authored >20 publications, and serves a variety of leadership functions for clinical rheumatology. Dr. Samuels received his medical degree from Cornell University Medical College in 1999.
| 1. | Evaluate the role of IL-6 inhibiting therapies in patients with RA for whom methotrexate and anti-TNF medications have failed. | 2. | Describe how the benefits of anti IL-6/IL-6R therapies may facilitate shared decision-making with patients and improve adherence. |
| 3. | Address potential concerns about the anti IL-6/IL-6R safety profile to overcome patient barriers to treatment. |
| 1. | Evaluate the role of IL-6 inhibiting therapies in patients with RA for whom methotrexate and anti-TNF medications have failed. |
| 2. | Describe how the benefits of anti IL-6/IL-6R therapies may facilitate shared decision-making with patients and improve adherence. |
| 3. | Address potential concerns about the anti IL-6/IL-6R safety profile to overcome patient barriers to treatment. |
This activity is intended for rheumatologists, PAs, NPs and nurses in rheumatology practices, and some internal medicine clinicians.
Educational Support
Disclosure of Conflicts of Interest
Planners and Managers
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There are no fees for participation in this CME activity. To receive credit, participants must 1) read the learning objectives and disclosure statements, 2) complete the educational activity and 3) complete the post-test and activity evaluation.
Internet
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
